Steel, who Dallas re-signed over the summer to a one-year deal, continued to demonstrate his versatility in the win.

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...